RU2019109570A3 - - Google Patents

Download PDF

Info

Publication number
RU2019109570A3
RU2019109570A3 RU2019109570A RU2019109570A RU2019109570A3 RU 2019109570 A3 RU2019109570 A3 RU 2019109570A3 RU 2019109570 A RU2019109570 A RU 2019109570A RU 2019109570 A RU2019109570 A RU 2019109570A RU 2019109570 A3 RU2019109570 A3 RU 2019109570A3
Authority
RU
Russia
Application number
RU2019109570A
Other languages
Russian (ru)
Other versions
RU2019109570A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019109570A publication Critical patent/RU2019109570A/ru
Publication of RU2019109570A3 publication Critical patent/RU2019109570A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2019109570A 2016-09-06 2017-09-02 8-(азетидин-1-ил)-[1,2,4]триазоло[1,5-а]пиридинилы, композиции и способы их применения RU2019109570A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016098215 2016-09-06
CNPCT/CN2016/098215 2016-09-06
PCT/EP2017/072034 WO2018046409A1 (en) 2016-09-06 2017-09-02 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
RU2019109570A RU2019109570A (ru) 2020-10-08
RU2019109570A3 true RU2019109570A3 (https=) 2020-10-08

Family

ID=59761965

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019109570A RU2019109570A (ru) 2016-09-06 2017-09-02 8-(азетидин-1-ил)-[1,2,4]триазоло[1,5-а]пиридинилы, композиции и способы их применения

Country Status (19)

Country Link
US (3) US20190202822A1 (https=)
EP (2) EP4198036A1 (https=)
JP (1) JP7050761B2 (https=)
KR (1) KR20190045302A (https=)
CN (1) CN109890817B (https=)
AU (1) AU2017324281A1 (https=)
BR (1) BR112019004486A2 (https=)
CA (1) CA3035712A1 (https=)
CL (1) CL2019000568A1 (https=)
CO (1) CO2019002171A2 (https=)
CR (1) CR20190118A (https=)
IL (1) IL265153A (https=)
MA (1) MA46176A (https=)
MX (1) MX2019002627A (https=)
PE (1) PE20190632A1 (https=)
PH (1) PH12019500478A1 (https=)
RU (1) RU2019109570A (https=)
SG (1) SG11201901954XA (https=)
WO (1) WO2018046409A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3986899A1 (en) * 2019-06-18 2022-04-27 F. Hoffmann-La Roche AG Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2024148184A1 (en) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Compounds and processes for the preparation of jak inhibitors
WO2024148186A1 (en) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Polymorphs of a jak1/tyk2 inhibitor and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US6034057A (en) 1995-07-06 2000-03-07 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
DE60214428T2 (de) 2001-12-20 2007-09-20 Bayer Healthcare Ag 1, 4-dihydro-1, 4-diphenylpyridin-derivate
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
CN102131389A (zh) 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
EP2438066A2 (en) * 2009-06-05 2012-04-11 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
HUE033587T2 (hu) * 2013-05-17 2017-12-28 Incyte Corp Bipirazol-származékok mint JAK inhibitorok
PE20161323A1 (es) * 2013-09-05 2016-11-25 Hoffmann La Roche Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos
JP2018507236A (ja) * 2015-03-04 2018-03-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft トリアゾロピリジン化合物及びその使用法

Also Published As

Publication number Publication date
RU2019109570A (ru) 2020-10-08
EP3510030B1 (en) 2023-03-22
US20190202822A1 (en) 2019-07-04
PE20190632A1 (es) 2019-04-26
MA46176A (fr) 2019-07-17
JP2019526593A (ja) 2019-09-19
AU2017324281A1 (en) 2019-03-21
PH12019500478A1 (en) 2019-12-02
US20230242530A1 (en) 2023-08-03
EP3510030A1 (en) 2019-07-17
US20200270248A1 (en) 2020-08-27
CR20190118A (es) 2019-04-30
CA3035712A1 (en) 2018-03-15
CO2019002171A2 (es) 2019-05-21
IL265153A (en) 2019-05-30
CN109890817A (zh) 2019-06-14
BR112019004486A2 (pt) 2019-05-28
CN109890817B (zh) 2022-06-17
EP4198036A1 (en) 2023-06-21
MX2019002627A (es) 2019-10-30
WO2018046409A1 (en) 2018-03-15
KR20190045302A (ko) 2019-05-02
JP7050761B2 (ja) 2022-04-08
CL2019000568A1 (es) 2019-07-12
SG11201901954XA (en) 2019-04-29

Similar Documents

Publication Publication Date Title
CH714036A1 (https=)
BR122021017409A2 (https=)
BR112019002665A2 (https=)
BR112019009263A2 (https=)
BR112018004966A2 (https=)
BR112019009262A2 (https=)
BR112019008087A2 (https=)
BR202017015425U2 (https=)
BR112019009373A2 (https=)
BR202016021748U2 (https=)
BE2016C010I2 (https=)
CN303536736S (https=)
CN303537567S (https=)
CN303536127S (https=)
CN303536212S (https=)
CN303536216S (https=)
CN303536221S (https=)
CN303572375S (https=)
CN303536284S (https=)
CN303536357S (https=)
CN303536361S (https=)
CN303536428S (https=)
CN303536593S (https=)
CN303536597S (https=)
CN303535548S (https=)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20210126